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Abstract: Vascular dementia (VaD) is the second most common form of dementia and is currently defined as a 
cerebral vessel vascular disease leading to ischemic episodes. Apolipoprotein E (apoE) gene polymorphism has 
been proposed as a risk factor for VaD, however, to date there are few documented post-mortem studies on apoE 
pathology in the VaD brain. To investigate a potential role for the apoE protein, we analyzed seven confirmed cases 
of VaD by immunohistochemistry utilizing an antibody that specifically detects the amino-terminal fragment of apoE. 
Application of this antibody, termed N-terminal, apoE cleavage fragment (nApoECF) revealed consistent labeling 
within neurofibrillary tangles (NFTs), blood vessels, and reactive astrocytes. Labeling occurred in VaD cases that had 
confirmed APOE genotypes of 3/3, 3/4, and 4/4, with respect to NFTs, staining of the nApoECF co-localized with 
PHF-1 and was predominantly localized to large, stellate neurons in layer II of the entorhinal cortex. Quantitative 
analysis indicated that approximately 38.4% of all identified NFTs contained the amino-terminal fragment of apoE. 
Collectively, these data support a role for the proteolytic cleavage of apoE in the VaD and support previous reports 
that APOE polymorphism is significantly associated with susceptibility in this disease.
Keywords: Vascular dementia, apoE, apolipoprotein E, neurofibrillary tangles, PHF-1, immunohistochemistry, 
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Introduction
Vascular dementia (VaD) is currently the sec-
ond leading cause of dementia in the USA, only 
trailing Alzheimer’s disease (AD) [1]. Diagnosing 
VaD is often difficult owing to the common co-
occurrence of VaD together with Alzheimer’s 
disease (AD), with an estimated 25-80% of all 
dementia cases showing mixed pathologies [2]. 
An additional confounding factor is that there 
are currently no widely accepted neuropatho-
logical criteria for VaD [3]. VaD is classified as a 
cerebral vessel vascular disease characterized 
by both large and small infarcts, lacunes, hip-
pocampal sclerosis, and white matter lesions 
[4]. The cognitive decline associated with VaD 
is thought to be the result of cerebral ische- 
mia secondary to the vascular pathologies 
aforementioned.
Behaviorally, patients with VaD show loss in 
executive functions as an initial symptom, 
whereas in AD memory loss is often associated 
with the earliest known symptoms. Other imp- 
ortant symptoms of VaD include confusion, lan-
guage deficits, restlessness and agitation, gait 
disturbances, and depression [5]. VaD predomi-
nantly affects patients with cardiovascular risk 
factors including hypertension [6, 7], hyperlipid-
emia [8], atherosclerosis [9], and diabetes [10-
12]. Stroke is also an important risk factor for 
dementia [13, 14] and the most common stroke 
subtype associated with VaD is lacunar stroke 
[15].
Human apolipoprotein E (apoE) is polymorphic 
with three major isoforms, apoE2, apoE3, and 
apoE4, which differ by single amino acid substi-
tutions involving cysteine-arginine replace-
ments at positions 112 and 158 [16]. In AD, 
inheritance of the APOE4 allele greatly increas-
es risk up to 10 fold if both alleles are present 
[17]. Human apoE has a major function in the 
CNS as a cholesterol transporter and therefore, 
would seem to be a logical risk factor for VaD. 
The loss of apoE function perhaps following pro-
teolytic cleavage is thought to be one potential 
mechanism by which apoE4 confers disease 
risk in AD [18]. However, whether apoE4 con-
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fers a similar risk for the VaD is currently unclear 
and despite the large number of studies exam-
ining whether harboring apoE4 is a risk factor 
for VaD, an exhaustive literature search failed 
to yield a single study examining apoE4 pathol-
ogy in the post-mortem VaD brain. The purpose 
of the present study was to determine the 
extent of apoE distribution in VaD using both 
full-length antibodies to apoE as well as an in 
house antibody that specifically detects the 
amino-terminal fragment of apoE [19]. Three 
consistent findings were observed using our 
cleavage apoE antibody in the VaD brain and 
included labeling within NFTs, blood vessels, 
and reactive astrocytes. These findings sug-
gest a potential role for apoE in contributing to 
the disease process underlying VaD.
Material and methods
Immunohistochemistry
Autopsy brain tissue from seven neuropatho-
logically confirmed VaD cases were studied. 
Case demographics are presented in Table 1. 
Fixed hippocampal tissue sections used in this 
study were provided by the Institute for Memory 
Impairments and Neurological Disorders at the 
University of California, Irvine. Free-floating 40 
μm-thick sections were used for immunohisto-
chemical studies as previously described [20]. 
No approval from Boise State University 
Institutional Review Board was obtained due to 
the exemption granted that all tissue sections 
were fixed and received from University of 
California, Irvine. Sections from the hippocam-
pus were selected for immunohistochemical 
analysis. 
For single labeling, all sections were washed 
with 0.1 M Tris-buffered saline (TBS), pH 7.4, 
and then pretreated with 3% hydrogen peroxide 
ECF antibody. Following two washes with TBS-A 
and a wash in TBS-B, sections were incubated 
in anti-rabbit or mouse biotinylated anti-IgG (1 
hour) and then in avidin biotin complex (1 hour) 
(ABC, Elite Immunoperoxidase, Vector Labora- 
tories, Burlingame, CA, USA). The primary anti-
body was visualized using brown DAB substrate 
(Vector Laboratories). 
Immunofluorescence microscopy
Primary antibodies utilized included the 
nApoECF (rabbit, 1:100), PHF-1 (mouse mono-
clonal, 1:1,000), anti-apoE4 C-terminal (rabbit, 
1:100), anti-apoE4 N-terminal (rabbit, 1:500), 
and anti-Ab mAb 1560 (clone 6E10, 1:400). 
The anti-Ab mAb 1560 (clone 6E10) was pur-
chased from Covance (Dedham, MA). The anti-
apoE4 C-terminal rabbit polyclonal antibody 
was purchased from Abgent (San Diego, CA). 
The anti-apoE4 N-terminal rabbit polyclonal 
antibody was purchased from Aviva Systems 
Biology Corp. (San Diego, CA). PHF-1 was a gen-
erous gift from Dr. Peter Davies (Albert Einstein 
College of Medicine, Bronx, NY).
Immunofluorescence studies were performed 
by incubating sections with primary antibo- 
dies overnight at a room temperature, followed 
by secondary anti-rabbit or mouse biotinylated 
anti-IgG (1 hour) and then in ABC (1 hour). 
Visualization was accomplished by using a tyra-
mide signal amplification kit (Molecular Pr- 
obes, Eugene, OR) consisting of Alexa Fluor 
488-labeled tyramide (green, Ex/Em = 495/ 
519). To visualize beta-amyloid staining, sec-
tions were pretreated for 5 minutes in 95% for-
mic acid. For immunofluorescence co-lo- 
calization studies, antigen visualization was 
accomplished using an Alexa fluor 488-labeled 
tyramide (green, Ex/Em = 495/519) for one 
label and streptavidin Alexa fluor 555 (red, Ex/
Table 1. Case Demographics
Case Age Sex PMI ApoE Genotype NPD Braak and Braak Plaque Stage
1 83 M 3.75 3/4 VaD Stage 1 Stage A
2 75 F 10.5 3/3 VaD Stage 2 None
3 83 M 12.4 4/4 VaD Stage 3 None
4 74 M 2.6 3/4 VaD Stage 2 Stage A
5 73 M 4.3 3/3 VaD Stage 0 None
6 88 M 9.9 3/4 VaD ND Stage A
7 85 F 3.4 3/3 VaD Stage 3 Stage B
PMI, postmortem interval in hours; NPD, neuropathological diagnosis, ND, not Determined.
in 10% methanol to blo- 
ck endogenous peroxi-
dase activity. Sections 
were subsequently wa- 
shed in TBS with 0.1% 
Triton X-100 (TBS-A) and 
then blocked for thirty 
minutes in TBS-A with 
3% bovine serum albu-
min (TBS-B). Sections 
were further incubated 
overnight at room tem-
perature with the nApo- 
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Em = 555/565) for the second label, both from 
Invitrogen (Carlsbad, CA). 
Statistical analysis
To determine the percent co-localization, quan-
titative analysis was performed as described 
previously [19, 20] by taking 20X immunofluo-
rescence, overlapping images from three differ-
ent fields in the hippocampus of four separate 
VaD cases. Capturing was accomplished by 
using a 2.5x photo eyepiece, a Sony high reso-
lution CCD video camera (XC-77). As an exam-
ple, to determine the percent co-localization 
between nApoECF and PHF-1, photographs 
were analyzed by counting the number of 
nApoECF-, PHF-1-positive NFTs alone per 20X 
Figure 1. Localization of an amino-terminal fragment of apoE in vascular disease. Application of the nApoECF 
antibody in hippocampal tissue sections from VaD cases revealed labeling predominantly within NFTs (arrows, A), 
blood vessels (B), and reactive astrocytes (C). For Panel A, Case #7 was utilized, which had an APOE genotype of 
3/3. Representative staining within blood vessels indicated a punctate labeling pattern following application of 
the nApoECF antibody (B, Case #5, APOE genotype, 3/3). For Panel C, Case #2 was use, which had a confirmed 
APOE genotype of 3/3. (D) Double-label immunofluorescence experiment utilizing the nApoECF antibody (arrows, 
green) together with Hoechst nuclear staining (arrowheads, blue) confirmed the punctate, irregular staining pattern 
of nApoECF within blood vessels. Note the appearance of cuboid, elongated nuclei that typically morphologically 
define endothelial cell nuclei (arrowheads). Rounder nuclei within the same regions most likely represent staining 
of nuclei from pericytes. For Panel D, Case #3 was utilized, which had a confirmed APOE genotype of 4/4. All scale 
bars represent 10 µm.
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nApoECF within NFTs (arrows, Figure 1A), blood 
vessels (Figure 1B), and within reactive astro-
cytes (Figure 1C). Labeling of nApoECF within 
blood vessels was punctate and irregular 
(Figure 1B and 1D). The relative intensity and 
distribution of nApoECF in all seven cases is 
shown in Table 2. It is noteworthy that the 
nApoECF antibody cannot distinguish between 
the three different isoforms of apoE and will 
readily recognize the cleavage of apoE3 and E4 
[19]. Although the general degree of nApoECF 
immunoreactive pathology appeared to be 
lower in those VaD cases defined as having 
APOE genotype of 3/3, strong immunolabeling 
was still observed in these cases (Table 2). 
However, overall it did appear that those cases 
determined to have the APOE genotype of 
either 3/4 or 4/4 exhibited a greater degree of 
nApoECF immunoreactive pathology (Table 2). 
Full-length apoE4 immunoreactive pathology
Utilizing VaD Case #3 with a confirmed APOE 
genotype if 4/4, we screened this case using 
full-length antibodies to the N- or C-terminal 
regions of the protein. Previous studies in AD 
have indicated a preferential localization of 
apoE4 antibodies such that N-terminal an- 
tibodies immunolabel both plaques and tan-
gles, while C-terminal antibodies immunolabel 
plaques only [21]. We confirmed these results 
in VaD as depicted in Figure 2. Application of 
the full-length N-terminal antibody to apoE4 
indicated staining within both NFTs (arrows, 
Figure 2A) and diffuse plaques (arrows, Figure 
2B). In contrast, no staining within NFTs was 
observed utilizing the full-length C-termi- 
nal antibody to apoE but strong labeling was 
observed within blood vessels (Figure 2C). To 
confirm the co-localization of the full-length 
N-terminal antibody to apoE with our in house 
cleavage apoE antibody, double-label immuno-
fluorescence studies were performed. 
Co-localization of both antibodies was evident 
within NFTs (Figure 2D-F). It is noteworthy that 
the nApoECF antibody did not label extracellu-
lar plaques in any VaD cases, as also previously 
demonstrated in the AD brain [19]. These data 
suggest that extracellular plaques are com-
posed principally of full-length apoE4.
Full-length apolipoprotein E immunoreactivity 
co-localizes with beta-amyloid both extra- and 
intracellularly
To confirm the presence of full-length apoE 
within extracellular plaques, double-label imm- 
unofluorescence experiments were performed. 
Table 2. Relative distribution of nApoECF 
labeling in VaD
Case NFTs Reactive Astrocyts Blood Vessels
1 +++ ++ ++
2 - +++ +++
3 +++ ++ +
4 + - ++
5 - - +++
6 +++ ++ +++
7 +++ - +
(-) Denotes absence of any labeling with nApoECF.
field for each case, and the number of cells 
labeled with both PHF-1 and nApoECF. Data are 
representative of the average number (±S.D.) of 
each antibody alone or co-localized with both 
antibodies in each 20X field (3 fields total for 4 
different cases). Statistical differences in this 
study were determined using Student’s two-
tailed T-test employing Microsoft Office Excel.
Results
Cleaved apoE immunoreactive pathology
Previous characterization of the nApoECF anti-
body indicated that it is highly specific for an 18 
kDa amino-terminal fragment of apoE [19]. This 
in house antibody was synthesized based upon 
a putative caspase-cleavage site (DADD) at 
position D172 of the full-length protein. App- 
lication of this antibody to AD frontal cortex 
brain sections revealed specific localiz- 
ation within neurofibrillary tangles (NFTs) that 
was dependent upon the APOE genotype: 
4/4≥3/4>3/3 [19]. However, in vitro cleavage 
of apoE4 by caspase-3 to generate an 18 kDa 
fragment detectable by the nApoECF antibody 
was unsuccessful [19] and the protease 
responsible for the in vivo cleavage of apoE4 is 
unknown at this time. To determine if amino-
terminal fragments of apoE can be detected in 
VaD, an immunohistochemical study utilizing 
the nApoECF antibody was performed utilizing 
fixed hippocampal brain sections from seven 
VaD cases. Case demographics for the VaD 
cases used in this study are presented in Table 
1. Notice that the APOE genotype was con-
firmed in all seven cases. All seven cases had a 
primary neuropathological diagnosis of VaD 
disease.
As an initial step, we screened all seven cases 
for nApoECF immunoreactivity using bright-field 
microscopy. Representative staining is depict-
ed in Figure 1 indicating consistent labeling of 
ApoE pathology in vascular dementia
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As shown in Figure 3, co-localization between 
the full-length amino-terminal apoE4 antibody 
and 6E10 was evident within extracellular 
plaques in VaD (Figure 3A-C). A quantitative 
analysis of this co-localization revealed that 
approximately 76.5% of all beta-amyloid 
plaques contained the full-length apoE protein 
(Figure 3H). Besides plaques, co-localization of 
6E10 and the full-length amino-terminal apoE 
antibody was also evident within blood vessels 
(Figure 3D), degenerating glial cells (Figure 3F), 
and within occasional NFTs (Figure 3G). 
Interesting, we also observed strong intracellu-
lar staining of the 6E10 antibody within neu-
rons of the hippocampus that did not co-local-
ize with the full-length apoE antibody (Figure 
3E).
Co-localization of the amino-terminal fragment 
apoE antibody with PHF-1, a marker for NFTs
Experiments were undertaken to determine the 
extent of localization of the nApoECF antibody 
within NFTs in VaD. As depicted in Figure 4, co-
localization between PHF-1 and nApoECF 
was evident within NFTs predominantly within 
layer II of the entorhinal cortex (Figure 4A-C). 
Interesting, co-localization was primarily res- 
erved in Stage 3 and 4 NFTs, in contrast to 
Stage 2 NFTs that were only labeled with PHF-1 
(Figure 3A-C). A quantitative analysis indicated 
that approximately 38.4% of all identified PHF-
labeled NFTs also labeled with the nApoECF 
antibody (Figure 4E). Rarely, did we observe the 
labeling of NFTs with the nApoECF antibody 
alone (Figure 4E). In addition to NFTs, PHF-1 
also strongly labeled neuritic plaques that con-
sisted of large PHF-1 labeled strands (asterisk, 
Figure 4D). These structures were never labeled 
with the nApoECF antibody.
Identified NFTs in VaD were large and region-
ally localized to the entorhinal cortex
Application of the PHF-1 antibody in VaD 
revealed labeling of large NFTs in layer II of the 
entorhinal cortex (Figure 5A). It is possible that 
these are stellate cells as they were often locat-
Figure 2. Characterization of apoE labeling in vascular disease utilizing full-length antibodies to both the C- and 
N-terminals regions to apoE. For all panels, representative labeling is shown utilizing Case #3, which had a confirmed 
APOE genotype of 4/4. (A and B) Representative staining following application of a full-length apoE antibody to 
the amino-terminal region of apoE revealed labeling within both NFTs (arrows, A) and diffuse plaques (arrows, B). 
(C) Identical to Panels A and B except for the use of a C-terminal full-length antibody to apoE indicating labeling 
predominantly within blood vessels. (D-F) Double-label immunofluorescence experiment employing our in house 
nApoECF antibody (green, D), amino-terminal full-length antibody to apoE (red, E), and the overlap image for the two 
antibodies indicating co-localization within apparent NFTs (arrows, F). All scale bars represent 10 µm.
ApoE pathology in vascular dementia
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ed in entorhinal cortex islands. As a compari-
son to the size of NFTs found in VaD, PHF-1 
labeling in a representative AD case is shown in 
Figure 5B. To validate these structures were 
indeed neuronal in nature, double-labeling exp- 
eriments were carried out utilizing NeuN, a spe-
cific nuclear marker for neuronal cells. 
Co-localization between PHF-1 and NeuN was 
evident within large NFTs of the entorhinal cor-
tex in the VaD brain (arrow, Figure 5C-E). 
Discussion
VaD is the seconding leading cause of demen-
tia in the USA [1], yet the causes of this form of 
dementia remain largely nebulous. Clearly, risk 
factors that increase the potential for strokes 
or microbleeds including hypertension, hyper-
lipidemia, and artherosclerosis are also impor-
tant risk factors for VaD [6-9]. One of the major 
roles of apoE is to transport cholesterol in the 
CNS, and therefore, it has been hypothesized 
that loss of function of apoE may contribute to 
a heightened risk for VaD as it does for AD [17]. 
In this manner, it has been hypothesized that 
proteolytic cleavage of apoE may lead to loss of 
function and functionally link the inheritance of 
the APOE4 allele to the heightened risk for AD 
[18]. Previous studies have indicated that apoE 
is more susceptible to proteolytic cleavage 
than the other isoforms of apoE [18]. However, 
attempts to link APOE polymorphism to enh- 
anced VaD risk have proven to be elusive as 
conflicting reports have emerged (For example 
see, [22-25]). Compounding these results is the 
paucity of studies examining apoE pathology in 
the VaD brain. Indeed, we were unable to 
Figure 3. Distribution of beta-amyloid deposition in the vascular disease brain. (A-D) To confirm the presence of 
plaques, double-immunofluorescence studies were carried out using an anti-beta-amyloid antibody, 6E10 (green, A) 
together with a full-length amino-terminal antibody to apoE (red, B) with the overlap image shown in (C). The orange/
yellow fluorescence in Panel C depicts where the two antibodies co-localize within plaques. (D) is identical to Panels 
A-C and depicts the labeling of apoE (arrows, yellow) predominantly within a blood vessel in which beta-amyloid 
plaques (arrowheads, green) are closely associated with in proximity. Representative immunofluorescence labeling 
in Panels A-D is shown utilizing Case #3, which had a confirmed APOE genotype of 4/4. (E-G) Besides plaques, 
application of 6E10 also indicated the presence of beta-amyloid within neurons with Hoechst nuclear staining 
(green, E, Case #4), degenerating glial cells (F, Case #1) and within NFTs (G, Case #1). Co-localization of 6E10 with 
full-length amino-terminal antibody was evident both within glial cells (F) and NFTs (G). (H) Quantification of plaques 
double-labeled by 6E10 and a full-length amino-terminal antibody to apoE. Data show the number of plaques labeled 
with the full-length apoE antibody alone (blue bar), 6E10 alone (green bar) or those plaques that were labeled with 
both antibodies (red bar). Plaques were identified in a 20X field within area CA1 by immunofluorescence overlap 
microscopy (n=3 fields for 4 different Pick cases) ±S.D., *p<0.05. Data indicated that roughly 76.5% of all identified 
plaques were labeled with both antibodies. All scale bars represent 10 µm except for Panel D, which represents 50 
µm.
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uncover a single study of apoE pathology in the 
VaD brain after an exhaustive literature search. 
Therefore, the primary purpose of this study 
was to examine apoE immunoreactive patholo-
gy in VaD utilizing a custom, in house antibody 
to the amino-terminal fragment of apoE as well 
as full-length antibodies.
Screening seven pathologically confirmed 
cases of VaD (Table 1) with our nApoECF anti-
body revealed three consistent staining fea-
tures: 1) punctate labeling within blood vessels; 
2) labeling of late-stage tangles primarily in 
layer II of the entorhinal cortex; 3) staining of 
reactive astrocytes. The staining within blood 
vessels was the most consistent finding utiliz-
ing the nApoECF antibody (Table 2) and sug-
gests that cleavage of apoE within blood ves-
sels could disrupt normal cholesterol transport 
and therefore, contribute to the cerebral vascu-
lar disease observed in this disease. Staining 
within reactive astrocytes may be indicative of 
the strong inflammatory component that has 
been associated with VaD [26]. In addition, a 
Figure 4. Co-localization of an amino-terminal fragment of apoE within NFTs of the vascular disease brain. (A-C) 
Representative immunofluorescence double-labeling in Case #1 identified as having an APOE genotype of 3/4. 
Utilizing the nApoECF antibody (green, Panel A) and PHF-1 (red, Panel B) revealed strong co-localization of the two 
antibodies within a NFT located in the entorhinal cortex (Panel C). Arrow in Panel C denotes a single-labeled tangle 
displaying vesicular punctate labeling with PHF-1 only. (D) Identical to Panel C illustrating co-localization of a single 
NFT (arrowhead) as well as the single-labeled, large NFT labeled with PHF-1 only. In addition, a neuritic plaque 
consisting of large PHF-1 labeled strands was evident within the field (asterisk, D). The representative staining 
shown in Panel D was accomplished using Case #6, which had a confirmed APOE genotype of 3/4. (E) Quantification 
of NFTs double-labeled by PHF-1 and nApoECF. Data show the number of NFTs labeled with nApoECF alone (blue 
bar), PHF-1 alone (green bar) or those NFTs that were labeled with both antibodies (red bar). NFTs were identified 
in a 20X field within hippocampal tissue sections by immunofluorescence overlap microscopy (n=3 fields using four 
different VaD cases) ±S.D., *p<0.05. Data indicated that roughly 38.4% of all identified NFTs were labeled with both 
antibodies. All scale bars represent 10 µm.
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previous study has documented the presence 
of extensive gliosis in the VaD brain supporting 
our current findings [27]. The finding of nApoECF 
within NFTs was not surprising, as this antibody 
strongly labels NFTs in the AD brain [19]. The 
localization of the nApoECF within NFTs was 
confirmed following co-localization experiments 
with PHF-1. In general, we observed three to 
four times less tangles in VaD as compared to 
AD. Thus, in a previous study we documented 
the presence of approximately 20-25 PHF-1-
labeled neurons per 20X field [19] as compared 
to the current study whereby only 6-7 PHF-1-
labeled neurons were documented (Figure 4E). 
Another interesting feature of PHF-1 labeling 
were the large size of neurons stained within 
clusters of layer II in the entorhinal cortex. 
These cells most likely are stellate neurons rep-
resenting an early stage in tangle pathology as 
has been previously described in Down’s syn-
drome [28]. The extent of co-localization 
between our nApoECF antibody and PHF-1 was 
only 38%. This value was much lower for the 
co-localization of the same two antibodies in 
AD, which we have previously reported to be 
60%. The overall low percent co-localization 
would suggest that the cleavage of apoE and 
tangle pathology is poorly correlated as sup-
ported by a calculated Pearson coefficient of 
0.27.
To verify the localization of our nApoECF anti-
body within NFTs, co-localization experiments 
were carried out using full-length antibodies to 
either the N- or C-terminal regions of apoE. As 
expected, we confirmed the co-localization of 
our in house antibody with the full-length 
N-terminal antibody but not the C-terminal anti-
body to apoE. Application of the full-length 
N-terminal apoE antibody to VaD cases also 
revealed strong immunolabeling within extra-
cellular plaques that co-localized with an anti-
beta-amyloid antibody, 6E10. An interesting 
feature of the nApoECF antibody is that it does 
not label extracellular plaques in the AD brain 
[19], nor did it label plaques observed in VaD. 
These data suggest that extracellular plaques 
consist primarily of full-length apoE, moreover, 
the presence of cleaved apoE within NFTs sup-
ports the hypothesis that the cleavage event of 
Figure 5. Presence of large, stellate neurofibrillary tangles in layer II of the entorhinal cortex in vascular dementia. (A, 
a and b) Representative single-label staining from VaD Case #1, showing staining in very large tangle-like structures 
in layer II of the entorhinal cortex. (B) As a comparison, the relative size of NFTs from an AD subject are shown 
following staining with PHF-1. Note the large size differential between the two types of tangles (Panel A vs. Panel B). 
(C-E) Double-label immunofluorescence experiments in VaD Case #1 utilizing the neuronal marker, NeuN, (green, C) 
together with PHF-1 (red, D), with the overlap image (arrow, E). All scale bars represent 10 µm.
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apoE occurs intracellularly or within blood ves-
sels, but not in the extracellular compartment. 
A final observation regarding apoE in the VaD 
brain that was shown in the present study was 
the staining of the nApoECF antibody in cases 
that had known genotypes of 3/3. Human apoE 
is polymorphic with three major isoforms, 
apoE2, apoE3, and apoE4, which differ by sin-
gle amino acid substitutions involving cysteine-
arginine replacements at positions 112 and 
158 [16]. Our in house nApoECF antibody rec-
ognizes the N-terminal fragment of apoE in 3/3 
and 3/4, and 4/4 genotypes [19]. In VaD, we 
observed widespread staining of the nApoECF 
in cases expressing all three different geno-
types (Table 2). However, there appeared to be 
a general trend for less apoE-immunoreactive 
pathology in VaD cases with known genotypes 
of 3/3 (Table 2). This is consistent with previ-
ous observations that apoE4 is highly suscep-
tible to proteolysis compared to the other major 
isoforms of apoE [29].
In conclusion, we have reported for the first 
time the presence of cleaved apoE in the VaD 
brain. The localization of an amino-terminal 
fragment of apoE was determined to largely be 
confined within NFTs, blood vessels, and reac-
tive astrocytes. ApoE immunoreactive patholo-
gy was documented in all seven VaD cases 
examined including those cases with a con-
firmed APOE genotype of 3/3. The presence of 
cleaved apoE within the hippocampus of VaD 
cases provides for pathological data support-
ing the potential link between APOE polymor-
phism and enhanced risk for VaD. In addition, 
the potential loss of function of apoE following 
cleavage may contribute to disease progres-
sion in a disorder whereby cerebral vascular 
risk factors play such an important role. 
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